Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Dapagliflozin is a member of the sodium-glucose cotransporter-2 (SGLT2) inhibitor class
antidiabetes agents which produces significant and sustained reductions in glycemic
parameters in patients with type 2 diabetes (T2DM). However, its non-glycemic effects are
still largely unknown.
The investigators will evaluate for the first time the effect of dapagliflozin on multiple
cardio-metabolic risk markers in one study. So far, no data on the effects of dapagliflozin
as well as other SGLT-2 inhibitors on subclinical atherosclerosis, endothelial function,
inflammatory markers, cytokines and atherogenic lipoproteins is available.
In addition, the investigators will examine microRNAs (miRNAs) implicated in the development
and progression of atherosclerotic disease. Again, no data is currently available on
dapaglifozin's as well as other SGLT-2 inhibitors' effects on miRNAs.
The results of this study will show for the first time the potential multiple, non-glycemic
effects of dapagliflozin, reducing multiple cardio-metabolic risk markers, which will
ultimately lead to decreased CV risk.
In addition, specific mechanisms of the dapagliflozin cardiovascular action will be
investigated.
Finally, the results of this study may pave the way for personalized therapy (using the
results on miRNAs).